SARS-CoV-2 Neutralizing Antibody for Wild Type and Variants

Description

SARS-CoV-2 Neutralizing Antibody for WT and Variants
Catalog number: B2010512
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 50 ug
Molecular Weight or Concentration: 150 kDa
Supplied as: Solution
Applications: molecular tool to study the immune response to SARS-CoV-2 and its variants
Storage: −20°C
Keywords: Spike Neutralizing Antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin
AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP Jr,
Bjorkman PJ. SARS-CoV-2 neutralizing antibody structures inform therapeutic
strategies. Nature. 2020 Dec;588(7839):682-687.

2: Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona
J, Mocherla B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L,
Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM;
BLAZE-1 Investigators. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients
with Covid-19. N Engl J Med. 2021 Jan 21;384(3):229-237.

3: Rodda LB, Netland J, Shehata L, Pruner KB, Morawski PA, Thouvenel CD,
Takehara KK, Eggenberger J, Hemann EA, Waterman HR, Fahning ML, Chen Y, Hale M,
Rathe J, Stokes C, Wrenn S, Fiala B, Carter L, Hamerman JA, King NP, Gale M Jr,
Campbell DJ, Rawlings DJ, Pepper M. Functional SARS-CoV-2-Specific Immune Memory
Persists after Mild COVID-19. Cell. 2021 Jan 7;184(1):169-183.e17.

4: Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and
Other Human Coronaviruses. Trends Immunol. 2020 May;41(5):355-359.

5: Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C,
Chai X, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L,
Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R,
Xie XS. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-
Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 2020
Jul 9;182(1):73-84.e16.

6: Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C,
Maggi F, Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical
pipeline. MAbs. 2020 Jan-Dec;12(1):1854149.

7: Deshpande GR, Sapkal GN, Tilekar BN, Yadav PD, Gurav Y, Gaikwad S, Kaushal H,
Deshpande KS, Kaduskar O, Sarkale P, Baradkar S, Suryawanshi A, Lakra R, Sugunan
AP, Balakrishnan A, Abraham P, Salve P. Neutralizing antibody responses to SARS-
CoV-2 in COVID-19 patients. Indian J Med Res. 2020 Jul & Aug;152(1 & 2):82-87.

8: Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against
the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020 Mar 15;16(10):1718-1723.
doi: 10.7150/ijbs.45123. PMID: 32226289; PMCID: PMC7098029.

9: Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q, Zhou J, Wu Y, Cai X, Qu D, Ying T,
Xie Y, Lu L, Yuan Z, Jiang S. RBD-Fc-based COVID-19 vaccine candidate induces
highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target
Ther. 2020 Nov 27;5(1):282.
10: Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O,
O’Byrne A, Kouphou N, Galao RP, Betancor G, Wilson HD, Signell AW, Winstone H,
Kerridge C, Huettner I, Jimenez-Guardeño JM, Lista MJ, Temperton N, Snell LB,
Bisnauthsing K, Moore A, Green A, Martinez L, Stokes B, Honey J, Izquierdo-
Barras A, Arbane G, Patel A, Tan MKI, O’Connell L, O’Hara G, MacMahon E,
Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD,
Neil SJD, Malim MH, Doores KJ. Longitudinal observation and decline of
neutralizing antibody responses in the three months following SARS-CoV-2
infection in humans. Nat Microbiol. 2020 Dec;5(12):1598-1607.

Products Related to SARS-CoV-2 Neutralizing Antibody for WT and Variants : SARS-CoV-2